Sznol M - Search Results

1

Resistance mechanisms to checkpoint inhibitors.

Weiss SA, Sznol M. Weiss SA, et al. Among authors: sznol m. Curr Opin Immunol. 2021 Apr;69:47-55. doi: 10.1016/j.coi.2021.02.001. Epub 2021 Mar 3. Curr Opin Immunol. 2021. PMID: 33676271 Review.

2

Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.

Flies DB, Sandler BJ, Sznol M, Chen L. Flies DB, et al. Among authors: sznol m. Yale J Biol Med. 2011 Dec;84(4):409-21. Yale J Biol Med. 2011. PMID: 22180678 Free PMC article. Review.

3

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Sznol M, Chen L. Sznol M, et al. Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063. Clin Cancer Res. 2013. PMID: 23460533 Free PMC article.

4

Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy.

Sznol M. Sznol M. Cancer J. 2014 Jul-Aug;20(4):290-5. doi: 10.1097/PPO.0000000000000056. Cancer J. 2014. PMID: 25098290 Review.

5

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. Kluger HM, et al. Among authors: sznol m. Clin Cancer Res. 2017 Aug 1;23(15):4270-4279. doi: 10.1158/1078-0432.CCR-16-3146. Epub 2017 Feb 21. Clin Cancer Res. 2017. PMID: 28223273 Free PMC article.

6

Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.

Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL. Smithy JW, et al. Among authors: sznol m. J Immunother Cancer. 2017 Mar 21;5:25. doi: 10.1186/s40425-017-0229-2. eCollection 2017. J Immunother Cancer. 2017. PMID: 28331615 Free PMC article.

7

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Sznol M, et al. Cancer Treat Rev. 2017 Jul;58:70-76. doi: 10.1016/j.ctrv.2017.06.002. Epub 2017 Jun 22. Cancer Treat Rev. 2017. PMID: 28689073 Free article. Review.

8

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Stamatouli AM, et al. Among authors: sznol m. Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002. Epub 2018 Jun 24. Diabetes. 2018. PMID: 29937434 Free PMC article. Review.

9

Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.

Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F Jr, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Siegel J, et al. Among authors: sznol m. J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17. J Am Acad Dermatol. 2018. PMID: 30025829

10

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Kluger HM, et al. Among authors: sznol m. J Clin Oncol. 2019 Jan 1;37(1):52-60. doi: 10.1200/JCO.18.00204. Epub 2018 Nov 8. J Clin Oncol. 2019. PMID: 30407895 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page